Reimbursement Briefs: Medicaid Savings, Kcentra Payment, Formulary Discrimination Concerns
Executive Summary
Cost reductions in Medicaid associated with increased drug use; Medicare add-on payments for Kcentra extended; patient groups seek formulary non-discrimination provisions in HHS rule.
You may also be interested in...
CBO Legislative Scores Will Account For Medicare Rx’s Reductions In Other Medical Costs
In a policy change, the Congressional Budget Office, which estimates the impact of legislation on federal spending, will account for pharmaceuticals’ effect on overall medical spending in Medicare for bills that directly affect drug use.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.